DK3113793T3 - Dna-vektor og transformerede tumorcellevacciner - Google Patents

Dna-vektor og transformerede tumorcellevacciner Download PDF

Info

Publication number
DK3113793T3
DK3113793T3 DK15712211.0T DK15712211T DK3113793T3 DK 3113793 T3 DK3113793 T3 DK 3113793T3 DK 15712211 T DK15712211 T DK 15712211T DK 3113793 T3 DK3113793 T3 DK 3113793T3
Authority
DK
Denmark
Prior art keywords
tumor cell
dna vector
cell vaccines
transformed tumor
transformed
Prior art date
Application number
DK15712211.0T
Other languages
English (en)
Inventor
Michael J P Lawman
Vijay Ramiya
Patricia D Lawman
Original Assignee
Morphogenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphogenesis Inc filed Critical Morphogenesis Inc
Application granted granted Critical
Publication of DK3113793T3 publication Critical patent/DK3113793T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK15712211.0T 2014-03-06 2015-03-04 Dna-vektor og transformerede tumorcellevacciner DK3113793T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461948980P 2014-03-06 2014-03-06
PCT/US2015/018688 WO2015134577A1 (en) 2014-03-06 2015-03-04 Dna vector and transformed tumor cell vaccines

Publications (1)

Publication Number Publication Date
DK3113793T3 true DK3113793T3 (da) 2021-01-18

Family

ID=52737394

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15712211.0T DK3113793T3 (da) 2014-03-06 2015-03-04 Dna-vektor og transformerede tumorcellevacciner

Country Status (4)

Country Link
US (2) US9555088B2 (da)
EP (1) EP3113793B1 (da)
DK (1) DK3113793T3 (da)
WO (1) WO2015134577A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168361A1 (en) * 2015-04-14 2016-10-20 Polynoma, Llc Polyvalent vaccines and combination therapy for the treatment of melanoma
US10682401B2 (en) 2015-05-19 2020-06-16 Morphogenesis, Inc. Multi-indication mRNA cancer immunotherapy
AU2016264363B2 (en) * 2015-05-19 2019-07-25 Morphogenesis, Inc. Cancer vaccine comprising mRNA encoding a M-like-protein
EP3618856A4 (en) * 2017-05-01 2021-02-24 Morphogenesis, Inc. MULTIPLE INDICATION MRNA CANCER IMMUNOTHERAPY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348015B2 (en) * 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
US7795020B2 (en) * 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines

Also Published As

Publication number Publication date
US9555088B2 (en) 2017-01-31
US20170136109A1 (en) 2017-05-18
WO2015134577A1 (en) 2015-09-11
US20160361400A1 (en) 2016-12-15
US9839680B2 (en) 2017-12-12
EP3113793A1 (en) 2017-01-11
EP3113793B1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
DK3597742T3 (da) Car-udtrykkende vektor og car-udtrykkende t-celler
DK3134131T3 (en) Nucleic acid vaccines
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3237418T3 (da) Triazolopyrimidinforbindelser og anvendelser deraf
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3333191T3 (da) Anti-C10ORF54-antistoffer og anvendelser deraf
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
SG11201605906UA (en) Muscle-specific nucleic acid regulatory elements and methods and use thereof
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3149025T3 (da) Cellepenetrerende peptider og fremgangsmåder til frembringelse og anvendelse deraf
DK3164774T3 (da) Fartøjshøjdebegrænsninger og styring
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3262066T4 (da) Genterapi
DK3198009T3 (da) Onkolytiske tumorvira og anvendelsesfremgangsmåder
DK3101760T3 (da) Opladningsfremgangsmåde og system
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3116911T3 (da) Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3240892T3 (da) Rpe-cellepopulationer og fremgangsmåder til dannelse deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3100050T3 (da) Immobiliserede proteiner og anvendelse deraf
DK3131577T3 (da) Modificerede værtsceller og anvendelser deraf
DK3233105T3 (da) Hidtil ukendt kombination og anvendelse
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
GB201416293D0 (en) Methods and preparations